U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda ...

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting ...

Profluent Bio's AI-driven protein design and IDT’s enzymology and genomics expertise unite to explore new paths for ...

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $80 million to fund Phase 2.

CN Bio, a leading provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix® Core.

Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in- ...

As mRNA continues to enter and be adopted by the global healthcare community, the need to quickly validate and scale these ...

Ventyx Biosciences, Inc. surged after strong Phase 2 results for VTX3232 in obesity. Click for key insights and what VTYX ...

First-time presentation examining bone outcomes in early postmenopausal women ...